|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01498 PURAPHARM
Nominal 
0.640 0.000 (0.000%) | 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Turnover | 406,859 | -9.197% | 448,069 | 659,592 | 601,815 | 695,879 |
| Cost of Sales | (190,230) | 2.625% | (185,365) | (236,239) | (231,866) | (297,040) |
| Gross Profit | 216,629 | -17.539% | 262,704 | 423,353 | 369,949 | 398,839 |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | (12,804) | 323.693% | (3,022) | -- | (229) | (19,063) | |
| Change in FV & Impairment on Others | (8,083) | -32.110% | (11,906) | (84,624) | (10,831) | (95,117) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (145) | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | (102,312) | -14.155% | (119,182) | (117,192) | 40,217 | (216,150) | |
| Taxation | (3,769) | 265.213% | (1,032) | (4,685) | (8,507) | (11,108) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (106,081) | -11.757% | (120,214) | (121,877) | 31,710 | (227,258) | |
| 2023/12 - Final HKD(K$) | %Chg (Compare to Final) | 2022/12 HKD(K$) | 2021/12 HKD(K$) | 2020/12 HKD(K$) | 2019/12 HKD(K$) | |
| Net Finance Costs / (Income) | 27,114 | 14.366% | 23,708 | 26,667 | 26,374 | 26,611 |
| Depreciation & Amortisation | 48,591 | -0.144% | 48,661 | 50,139 | 47,626 | 66,755 |
| Directors' Emoluments | 11,677 | 58.784% | 7,354 | 12,470 | 11,658 | 8,099 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -26.850 | -11.881% | -30.470 | -30.950 | 8.550 | -87.160 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.202 | -- | 0.224 | (0.037) | 0.323 | 0.503 |
| NBV per share ($) | 0.387 | -- | 0.652 | 1.017 | 1.296 | 1.299 |
| Remarks: | Real time quote last updated: 22/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD -18,686,000 |
| %Change | -50.402% |
| EPS / (LPS) | HKD -0.047 |
| NBV Per Share ($) | HKD 0.330 |